Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery

NCT03750071 is registered in ClinicalTrials.gov with Vaximm GmbH as lead sponsor.

NCT NCT03750071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03750071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
Lead sponsor
Vaximm GmbH
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 21, 2018
Completion date
December 31, 2022
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma